Jong Hoon Kim

List of Publications by Year
in descending order

92	2,027	331670 21	265206 42
papers	citations	h-index	g-index

93	93	93	3192
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2014, 15, 1245-1253.	10.7	336
2	Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. JAMA Oncology, 2018, 4, 661.	7.1	311
3	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 3111-3123.	1.6	100
4	Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 876-883.	0.8	86
5	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 320-329.e6.	0.5	75
6	Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver International, 2017, 37, 90-100.	3.9	58
7	Stereotactic body radiation therapy for small (â‰¤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clinical and Molecular Hepatology, 2020, 26, 506-515.	8.9	52
8	Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS ONE, 2019, 14, e0214970.	2.5	45
9	Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiation Oncology, 2015, 10, 238.	2.7	42
10	Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 489-496.	0.8	39
11	Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. Radiotherapy and Oncology, 2016, 118, 408-415.	0.6	38
12	Prognostic and Oncologic Significance of Perineural Invasion in Sporadic Colorectal Cancer. Annals of Surgical Oncology, 2017, 24, 1626-1634.	1.5	37
13	High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget, 2017, 8, 15182-15192.	1.8	35
14	Postoperative Chemoradiotherapy for Extrahepatic Bile Duct Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 696-704.	0.8	32
15	Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography. PLoS ONE, 2014, 9, e90327.	2.5	31
16	Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer, 2018, 18, 416.	2.6	30
17	Efficacy and safety of ultrasound-guided implantation of fiducial markers in the liver for stereotactic body radiation therapy. PLoS ONE, 2017, 12, e0179676.	2.5	30
18	A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2019, 37, 4027-4027.	1.6	28

#	Article	IF	Citations
19	Controversial issues in radiotherapy for rectal cancer: a systematic review. Radiation Oncology Journal, 2017, 35, 295-305.	1.5	27
20	Synchronous second primary cancers in patients with squamous esophageal cancer: clinical features and survival outcome. Korean Journal of Internal Medicine, 2016, 31, 253-259.	1.7	24
21	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). Anticancer Research, 2019, 39, 5123-5133.	1.1	23
22	Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). PLoS ONE, 2016, 11, e0152642.	2.5	22
23	Liver Transplantation After Transarterial Chemoembolization and Radiotherapy for Hepatocellular Carcinoma with Vascular Invasion. Journal of Gastrointestinal Surgery, 2017, 21, 275-283.	1.7	22
24	Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1953-1959.	2.8	19
25	Impact of a Multidisciplinary Team Approach for Managing Advanced and Recurrent Colorectal Cancer. World Journal of Surgery, 2018, 42, 2227-2233.	1.6	18
26	Radiation-induced esophageal strictures treated with fluoroscopic balloon dilation: clinical outcomes and factors influencing recurrence in 62 patients. Acta Radiologica, 2018, 59, 313-321.	1.1	18
27	Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. Radiotherapy and Oncology, 2019, 141, 95-100.	0.6	17
28	Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 505-516.	3.0	17
29	Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Annals of Hematology, 2017, 96, 1509-1515.	1.8	15
30	Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). Oncotarget, 2017, 8, 94450-94461.	1.8	15
31	Targeting Accuracy of Image-Guided Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Real-Life Clinical Practice: InÂVivo Assessment Using Hepatic Parenchymal Changes on Gd-EOB-DTPAâ€"Enhanced Magnetic Resonance Images. International Journal of Radiation Oncology Biology Physics, 2018, 102, 867-874.	0.8	15
32	Feasibility and Outcome of Concurrent Chemoradiotherapy for Recurrent Cervical Carcinoma after Initial Surgery. Tumori, 2010, 96, 553-559.	1.1	14
33	Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis. BMC Cancer, 2015, 15, 987.	2.6	14
34	Radiofrequency ablation versus stereotactic body radiation therapy for small (â‰¤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1962-1970.	2.8	14
35	Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer. BMC Cancer, 2021, 21, 413.	2.6	14
36	Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report. Radiation Oncology Journal, 2013, 31, 199.	1.5	14

#	Article	IF	Citations
37	Role of fractionated radiotherapy in patients with hemangioma of the cavernous sinus. Radiation Oncology Journal, 2017, 35, 268-273.	1.5	14
38	The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 57-64.	1.0	13
39	Gated Volumetric-Modulated Arc Therapy vs. Tumor-Tracking CyberKnife Radiotherapy as Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Dosimetric Comparison Study Focused on the Impact of Respiratory Motion Managements. PLoS ONE, 2016, 11, e0166927.	2.5	13
40	Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration. Scientific Reports, 2018, 8, 16224.	3.3	13
41	Prognostic Factors in Terms of the Number of Metastatic Nodules in Patients With Colorectal Cancer Liver Metastases. Annals of Coloproctology, 2016, 32, 92.	2.0	13
42	Postoperative radiotherapy for gallbladder cancer. Anticancer Research, 2014, 34, 5621-9.	1.1	13
43	Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. Cancer Research and Treatment, 2014, 46, 348-357.	3.0	12
44	Effectiveness of adjuvant radiotherapy after local excision of rectal cancer with deep submucosal invasion: a single-hospital, caseâ€“control analysis. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 3231-3238.	2.4	11
45	Hepatic reaction dose for parenchymal changes on <scp>G</scp>dâ€<scp>EOB</scp>â€<scp>DTPA</scp>â€enhanced magnetic resonance images after stereotactic body radiation therapy for hepatocellular carcinoma. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 96-101.	1.8	11
46	Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer. Radiation Oncology Journal, 2014, 32, 70.	1.5	10
47	Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study. Radiation Oncology Journal, 2014, 32, 198.	1.5	10
48	Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer. Radiation Oncology Journal, 2016, 34, 177-185.	1.5	10
49	Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 289-295.	0.8	8
50	Restaging Abdominopelvic Computed Tomography Before Surgery After Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, 259.	7.1	8
51	Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. PLoS ONE, 2015, 10, e0135298.	2.5	8
52	Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases. Cancer Research and Treatment, 2022, 54, 850-859.	3.0	8
53	Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study. Radiotherapy and Oncology, 2021, 162, 112-118.	0.6	7
54	Refining prognostic stratification of human papillomavirus-related oropharyngeal squamous cell carcinoma: different prognosis between T1 and T2. Radiation Oncology Journal, 2017, 35, 233-240.	1.5	7

#	Article	IF	Citations
55	Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy. Cancer Research and Treatment, 2021, , .	3.0	7
56	Incidence and Dose-volume Analysis of Acute Bladder Toxicity following Pelvic Radiotherapy. Tumori, 2014, 100, 195-200.	1.1	6
57	Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: AÂPropensity Scoreâ€“Matched Analysis. International Journal of Radiation Oncology Biology Physics, 2018, 101, 630-639.	0.8	6
58	Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma. BMC Cancer, 2018, 18, 1040.	2.6	6
59	How to Combine Diffusion-Weighted and T2-Weighted Imaging for MRI Assessment of Pathologic Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. Korean Journal of Radiology, 2021, 22, 1451.	3.4	6
60	Geometric and dosimetric verification of a recurrent neural network algorithm to compensate for respiratory motion using an articulated robotic couch. Journal of the Korean Physical Society, 2021, 78, 64-72.	0.7	6
61	Recurrence patterns of mucose-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience. Hematology, 2016, 21, 542-548.	1.5	5
62	Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in â€œEarlyâ€•Clinical T3 Rectal Cancer: A Propensity Score Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 136-144.	0.8	5
63	Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. Current Problems in Cancer, 2021, 45, 100685.	2.0	5
64	Patterns of recurrence after radiation therapy for high-risk neuroblastoma. Radiation Oncology Journal, 2019, 37, 224-231.	1.5	5
65	Evaluation of delivered dose to a moving target by 4D dose reconstruction in gated volumetric modulated arc therapy. PLoS ONE, 2018, 13, e0202765.	2.5	4
66	Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial. BMC Cancer, 2019, 19, 404.	2.6	4
67	Identification of Induced-Radioactivity in Medical LINAC Using a NaI(Tl)-Crystal Detector. Progress in Nuclear Science and Technology, 2011, 1, 525-528.	0.3	4
68	Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy. Korean Journal of Internal Medicine, 2017, 32, 443-451.	1.7	4
69	Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer, 2022, 22, 175.	2.6	4
70	LINAC-based High-precision Radiotherapy: Radiosurgery, Image-guided Radiotherapy, and Respiratory-gated Radiotherapy. Journal of the Korean Medical Association, 2008, 51, 612.	0.3	3
71	Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer. Radiation Oncology Journal, 2017, 35, 129-136.	1.5	3
72	Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Anticancer Research, 2017, 37, 755-764.	1.1	3

#	Article	IF	Citations
73	Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series. Clinical Endoscopy, 2018, 51, 470-477.	1.5	3
74	Long-term oncologic and complication outcomes in anal cancer patients treated with radiation therapy. Journal of Cancer Research and Therapeutics, 2020, 16, 194.	0.9	3
75	Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Cancers, 2022, 14, 1166.	3.7	3
76	Efficacy of preoperative chemoradiotherapy in patients with cT2N0 distal rectal cancer. Annals of Coloproctology, 2023, 39, 250-259.	2.0	3
77	Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e53-e62.	1.1	2
78	Radiation therapy for recurrent extrahepatic bile duct cancer. PLoS ONE, 2021, 16, e0253285.	2.5	2
79	Postoperative radiotherapy for gallbladder cancer.. Journal of Clinical Oncology, 2013, 31, 289-289.	1.6	2
80	The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean Journal of Thoracic and Cardiovascular Surgery, 2020, 53, 160-167.	0.6	2
81	Gemcitabine-Related Radiation Recall in a Patient with Metastatic Non-small Cell Lung Cancer. Journal of Lung Cancer, 2008, 7, 98.	0.2	1
82	Response to Is radiotherapy the best option for treating hepatocellular carcinoma with <scp>PVTT</scp>?. Liver International, 2017, 37, 308-309.	3.9	1
83	Patterns of recurrence in patients with curative resected rectal cancer according to different chemoradiotherapy strategies: Does preoperative chemoradiotherapy lower the risk of peritoneal recurrence?. Oncology Letters, 2020, 20, 1-1.	1.8	1
84	Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. Cancer Medicine, 2021, 10, 1745-1758.	2.8	1
85	Prognostic significance of lymph node ratio after neoadjuvant chemoradiation therapy for esophageal squamous cell carcinoma. Radiation Oncology Journal, 2020, 38, 244-252.	1.5	1
86	Novel endoscopic categorization for prediction of chemoradiotherapy response in locally advanced esophageal cancer. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1213-1219.	2.8	0
87	Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer. Radiation Oncology Journal, 2021, 39, 202-209.	1.5	0
88	Phase I study of preoperative chemoradiation with temozolomide and capecitabine in patients with locally advanced rectal cancer.. Journal of Clinical Oncology, 2015, 33, 3569-3569.	1.6	0
89	Stereotactic body radiation therapy for local control of liver metastases from colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 662-662.	1.6	0
90	Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial.. Journal of Clinical Oncology, 2018, 36, 210-210.	1.6	0

#	Article	IF	Citations
91	Combined radiotherapy and transarterial chemoembolization as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion.. Journal of Clinical Oncology, 2019, 37, 452-452.	1.6	0
92	Preoperative chemoradiotherapy with capecitabine with or without temozolomide in patients with locally advanced rectal cancer: A prospective, randomized phase 2 study stratified by MGMT (O⁶-methylguanine DNA methyltransferase) status: KCSG-CO17-02.. Journal of Clinical Oncology, 2022, 40, 3605-3605.	1.6	0